Stocks · US
CRL
XNYS
Charles River Laboratories International, Inc.
An overview for this page is not available in English yet. The figures below are updated daily.
Key figures 2026-10-06 basis
P/E—
P/B5.22x
P/S3.71x
EPS$-5.00
ROE-8.40%
ROA-3.17%
Dividend yield0.00%
EV/EBITDA22.60x
Debt/Equity0.92
Free cash flow$371M
Returns and 52-week range
1W+3.04%
1M+5.71%
3M+36.17%
6M+79.87%
1Y+71.97%
YTD+50.66%
52W high$333.30
52W low$146.19
From 52W high-8.50%
Company
Peers in the same sector
| Company | Market cap | P/E | P/B | 1M |
|---|---|---|---|---|
| Solventum Corporation | $15.0B | 10.45 | 3.12 | -5.07% |
| Neurocrine Biosciences Inc | $14.7B | 20.78 | 3.97 | -6.51% |
| 템퍼스 AI | $15.2B | — | 34.09 | +11.39% |
| Exelixis Inc | $14.6B | 16.94 | 7.91 | -1.15% |
| Jazz Pharmaceuticals, Inc. | $15.3B | 16.29 | 3.19 | -6.25% |
| 트위스트 바이오사이언스 | $13.6B | — | 30.49 | +33.88% |
Sources and notes
This page summarizes public filings, market data and news for information only. It is not a recommendation to buy or sell any security. Figures are as of the dates shown; check the original filings before making decisions.